Selenorhodamine photosensitizers for photodynamic therapy of P-glycoprotein-expressing cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8622-8634

  Hill, Jacqueline E ^a   Linder, Michelle K ^a   Davies, Kellie S ^a   Sawada, Geri A ^b   Morgan, Janet ^c   Ohulchanskyy, Tymish Y ^a   Detty, Michael R ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [5 (DIETHYLCARBAMOTHIOYL)THIOPHEN 2 YL] SELENORHODAMINE; 9 [5 (DIETHYLCARBAMOYL)THIOPHEN 2 YL] SELENORHODAMINE; 9 [5 (IPERIDYLCARBAMOYL)THIOPHEN 2 YL] SELENORHODAMINE; 9 [5 (PIPERIDYLCARBAMOTHIOYL)THIOPHEN 2 YL] SELENORHODAMINE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PHOTOSENSITIZING AGENT; RHODAMINE; SELENIUM DERIVATIVE; SINGLET OXYGEN; THIOAMIDE; UNCLASSIFIED DRUG; VERAPAMIL; ORGANOSELENIUM DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SYNTHESIS; DYE LASER; EC50; FLOW CYTOMETRY; HISTOGRAM; LD 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; TRANSFORMED CELL; ANIMAL; CHEMISTRY; DOG; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; MDCK CELL LINE; METABOLISM; MOUSE; PHOTOCHEMOTHERAPY; PROCEDURES; SPECTROFLUOROMETRY; SYNTHESIS; TOXICITY TESTING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DOGS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MICE; ORGANOSELENIUM COMPOUNDS; P-GLYCOPROTEIN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RHODAMINES; SINGLET OXYGEN; SPECTROMETRY, FLUORESCENCE; TOXICITY TESTS; VERAPAMIL;

EID: 84908377341     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501259v     Document Type: Article

References (54)

1. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
2. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
3. Abolhoda, A.; Wilson, A. I.; Ross, H.; Danenberg, P. V.; Burt, M.; Scotto, K. W. Rapid activiation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin Clin. Cancer Res. 1999, 5, 3352-3356
4. Raub, T. J. P-Glycoprotein recognition of substrates and circumvention through rational drug design Mol. Pharmaceutics 2006, 3, 3-25
5. Seelig, A.; Gatlik-Landwojtowicz, E. Inhibitors of multidrug efflux transporters: their membrane and protein interactions Mini-Rev. Med. Chem. 2005, 5, 135-151
6. Dantzig, A. H.; de Alwis, D. P.; Burgess, M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy Adv. Drug Delivery Rev. 2003, 55, 133-150
7. Loetchutinat, C.; Saengkhae, C.; Marbeuf-Gueye, C.; Garnier-Suillerot, A. New insights into the P-glycoprotein-mediated effluxes of rhodamines Eur. J. Biochem. 2003, 270, 476-485
8. Eytan, G. D.; Regev, R.; Hurwitz, C. D.; Assaraf, Y. G. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate Eur. J. Biochem. 1997, 248, 104-112
9. Lu, P.; Liu, R.; Sharom, F. J. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state Eur. J. Biochem. 2001, 268, 1687-1695
10. Johnson, L. V.; Walsh, M. L.; Bockus, B. J.; Chen, L. B. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy J. Cell Biol. 1981, 88, 526-535
11. Davis, S.; Weiss, M. J.; Wong, J. R.; Lampidis, T. J.; Chen, L. B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by breast adenocarcinoma-derived MCF-7 cells J. Biol. Chem. 1985, 260, 13844-13850
12. Lampidis, T. J.; Bernal, S. D.; Summerhayes, I. C.; Chen, L. B. Selective toxicity of rhodamine-123 in carcinoma cells in vitro Cancer Res. 1983, 43, 716-720
13. Bernal, S. D.; Lampidis, T. J.; McIsaac, R. M.; Chen, L. B. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye Science 1986, 222, 169-172
14. Sun, X.; Wong, J. R.; Song, K.; Hu, J.; Garlid, K. D.; Chen, L. B. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity Cancer Res. 1994, 54, 1465-1471
15. Detty, M. R.; Gibson, S. L.; Wagner, S. J. Current clinical and preclinical photosensitizers for use in photodynamic therapy J. Med. Chem. 2004, 47, 3987-3915
16. Pal, P.; Zeng, H.; Durocher, G.; Girard, D.; Li, T. C.; Gupta, A. K.; Giasson, R.; Blanchard, L.; Gaboury, L.; Balassy, A.; Turmel, C.; Laperriere, A.; Villeneuve, L. Phototoxicity of some bromine-substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers Photochem. Photobiol. 1996, 63, 161-168
17. Ohulchanskyy, T.; Donnelly, D. J.; Detty, M. R.; Prasad, P. N. Heteroatom substitution changes in excited-state photophysics and singlet oxygen generation in chalcogenoxanthylium dyes: effect of sulfur and selenium substitutions J. Phys. Chem. B 2004, 108, 8668-8672
18. Kessel, D.; Woodburn, K. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitizing agent Br. J. Cancer 1995, 71, 306-310
19. Ogata, M.; Inanami, O.; Nakajima, M.; Nakajima, T.; Hiraoka, W.; Kuwabara, M. Ca2+-dependent and caspace-3-independent apoptosis caused by damage in Golgi apparatus due to 2,4,5,7-tetrabromorhodamine 123 bromide-induced photodynamic effects Photochem. Photobiol. 2003, 78, 241-247
20. Solomon, S. R.; Mielke, S.; Savani, B. N.; Montero, A.; Wisch, L.; Childs, R.; Hensel, N.; Schindler, J.; Ghetie, V.; Leitman, S. F.; Mai, T.; Carter, C. S.; Kurlander, R.; Read, E. J.; Vitetta, E. S.; Barrett, A. J. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation Blood 2005, 106, 1123-1129
21. Mielke, S.; Nunes, R.; Rezvani, K.; Fellowes, V. S.; Venne, A.; Solomon, S. R.; Fan, Y.; Gostick, E.; Price, D. A.; Scotto, C.; Read, E. J.; Barrett, A. J. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique Blood 2008, 111, 4392-4402
22. Detty, M. R.; Prasad, P. N.; Donnelly, D. J.; Ohulchanskyy, T.; Gibson, S. L.; Hilf, R. Synthesis, properties, and photodynamic properties in vitro of heavy-chalcogen analogues of tetramethylrosamine Bioorg. Med. Chem. 2004, 12, 2537-2544
23. Scala, S.; Akhmed, N.; Rao, U. S.; Paull, K.; Lan, L.-B.; Dickstein, B.; Lee, J.-S.; Elgemeie, G. H.; Stein, W. D.; Bates, S. E. P-glycoprotein substrates and antagonists cluster into two distinct groups Mol. Pharmacol. 1997, 51, 1024-1033
24. Lee, J. S.; Paull, K.; Alvarez, M.; Hose, C.; Monks, A.; Grever, M.; Fojo, A. T.; Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol. Pharmacol. 1994, 46, 627-638
25. Shapiro, A. B.; Ling, V. Stoichiometry of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein Eur. J. Biochem. 1998, 254, 189-193
26. Shapiro, A. B.; Ling, V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities Eur. J. Biochem. 1997, 250, 130-137
27. Tombline, G.; Donnelly, D. J.; Holt, J. J.; You, Y.; Ye, M.; Gannon, M. K.; Nygren, C. L.; Detty, M. R. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state Biochemistry 2006, 45, 8034-8047
28. Tombline, G.; Holt, J. J.; Gannon, M. K., II; Donnelly, D. J.; Wetzel, B.; Sawada, G. A.; Raub, T. J.; Detty, M. R. ATP occlusion as a surrogate measure for drug coupling Biochemistry 2008, 47, 3294-3307
29. Gannon, M. K., II; Holt, J. J.; Bennett, S. M.; Wetzel, B. R.; Loo, T. W.; Bartlett, M. C.; Clarke, D. M.; Sawada, G. A.; Higgins, J. W.; Tombline, G.; Raub, T. J.; Detty, M. R. Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity J. Med. Chem. 2009, 52, 3328-3341
30. Orchard, A.; Schamerhorn, G. A.; Calitree, B. D.; Sawada, G. A.; Loo, T. W.; Bartlett, M. C.; Clarke, D. M.; Detty, M. R. Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1) Bioorg. Med. Chem. 2012, 20, 4290-4302
31. Gorman, A.; Killoran, J.; O'Shea, C.; Kenna, T.; Gallagher, W. M.; O'Shea, D. F. In vitro demonstration of the heavy-atom effect for photodynamic therapy J. Am. Chem. Soc. 2004, 126, 10619-10631
32. Leonard, K. A.; Hall, J. P.; Nelen, M. I.; Davies, S. R.; Gollnick, S. O.; Camacho, S.; Oseroff, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization J. Med. Chem. 2000, 43, 4488-4498
33. Brennan, N. K.; Hall, J. P.; Davies, S. R.; Gollnick, S. O.; Oseroff, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1 J. Med. Chem. 2002, 45, 5123-5135
34. Detty, M. R.; Gibson, S. L.; Hilf, R. Comparison of the dark and light-induced toxicity of thio and seleno analogues of the thiopyrylium dye AA1 Bioorg. Med. Chem. 2004, 12, 2589-2596
35. Holt, J. J.; Gannon, M. K.; Tombline, G.; McCarty, T. A.; Page, P. M.; Bright, F. V.; Detty, M. R. A cationic chalcogenoxanthylium photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells Biorg. Med. Chem. 2006, 14, 8635-8643
36. Kryman, M. W.; Schamerhorn, G. A.; Hill, J. E.; Calitree, B. D.; Davies, K. S.; Linder, M. K.; Ohulchanskyy, T. Y.; Detty, M. R. Synthesis and properties of heavy chalcogen analogues of the Texas reds and related rhodamines Organometallics 2014, 33, 2628-2640
37. Beak, P.; Brown, R. A. The tertiary amide as an effective director of ortho lithiation J. Org. Chem. 1982, 47, 34-36
38. Carpenter, A. J.; Chadwick, D. J. High yield syntheses of 2,3-disubstituted furans and thiophenes Tetrahedron Lett. 1985, 26, 1777-1980
39. Katritzky, A. R.; Witek, R. M.; Rodriguez-Garcia, V.; Mohapatra, P. P.; Rogers, J. W.; Cusido, J.; Abdel-Fattah, A. A. A.; Steel, P. J. Benzotriazole-assisted thioacylation J. Org. Chem. 2005, 70, 7866-7881
40. Magde, D. R.; Wong, R.; Seybold, P. G. Fluorescence quantum yields and their relation to lifetimes of rhodamine 6G and fluorescein in nine solvents: improved absolute standards for quantum yields Photochem. Photobiol. 2002, 75, 327-334
41. Partition Coefficients: Sangster, J. In Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry; Fogg, P. G. T., Ed.; Wiley Series in Solution Chemistry, Vol. 2; John Wiley and Sons: New York, 1997.
42. Spoelstra, E. C.; Dekker, H.; Schuurhuis, G. J.; Broxterman, H. J.; Lankelma, J. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport Biochem. Pharmacol. 1991, 41, 349-359
43. Evers, R.; Kool, M.; Smith, A. J.; van Deemter, L.; de Haas, M.; Borst, P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1Pgp-, MRP1- and MRP2-mediated transport Br. J. Cancer 2000, 83, 366-374
44. Houghton, P.; Fang, R.; Techatanawat, I.; Steventon, G.; Hylands, P. J.; Lee, C. C. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity Methods 2007, 42, 377-387
45. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protoc. 2006, 1, 1112-1116
46. Sawada, G. A.; Barsuhn, C. L.; Lutzke, B. S.; Houghton, M. E.; Padbury, G. E.; Ho, N. F. H.; Raub, T. J. Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants J. Pharmacol. Exp. Ther. 1999, 288, 1317-1326
47. Dantzig, A. H.; Shepard, R. L.; Law, K. L.; Tabas, L.; Pratt, S.; Gillespie, J. S.; Binkley, S. N.; Kuhfeld, M. T.; Starling, J. J.; Wrighton, S. A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P450 activities J. Pharmacol. Exp. Ther. 1999, 290, 854-890
48. Riddell, J. R.; Wang, X.-Y.; Hans Minderman, H.; Gollnick, S. O. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4 J. Immunol. 2010, 184, 1022-1030
49. Wagner, S. J.; Skripchenko, A.; Donnelly, D. J.; Ramaswamy, K.; Detty, M. R. Chalcogenoxanthylium photosensitizers for the photodynamic purging of blood-borne viral and bacterial pathogens Bioorg. Med. Chem. 2005, 13, 5927-5935
50. Wagner, S. J.; Skripchenko, A.; Thompson-Montgomery, D.; Awatefe, H.; Donnelly, D. J.; Detty, M. R. Use of a red cell band 3-ligand/antioxidant to improve red cell storage properties following virucidal phototreatment with chalcogenoxanthylium photosensitizers for pathogen reduction Photochem. Photobiol. 2006, 76, 514-517
51. Calitree, B. D.; Donnelly, D. J.; Holt, J. J.; Gannon, M. K., II; Nygren, C.; Sukumaran, D. K.; Autschbach, J.; Detty, M. R. Tellurium analogues of rosamine and rhodamine dyes: synthesis, structure, 125Te NMR, and heteroatom contributions to excitation energies Organometallics 2007, 26, 6248-6257
52. Weiss, R. B. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-686
53. Jordon, M. A. Anti-cancer agents Cur. Med. Chem. 2002, 2, 1-17
54. Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J. S. Doxorubicin cardiomyopathy Cardiology 2010, 115, 155-162